Cecelia Health’s Post

A16z Bio podcasts on Glp-1s

As Ozempic, Wegovy, Mounjaro, and Zepbound capture the healthcare spotlight, we’ve developed a series of episodes that go beyond the headlines and take you into conversations with the specialists. 🔬 The Science of Satiety with Carolyn Bradner Jasik, MD: Vijay Pande, PhD and Carolyn discuss the science behind GLP-1s and their implications for obesity treatment highlighting the excitement in the medical community and the potential for GLP-1s to transform weight loss treatment while underscoring the importance of behavior change. Listen here: https://lnkd.in/g-z_jtP3 💡 Patient-Centered Care for Obesity with Brooke Boyarsky Pratt: Brooke, alongside Vineeta Agarwala, MD PhD, emphasizes the necessity of creating a holistic, evidence-based approach to treating obesity. She shares insights on how patient experiences can be improved through personalized care and the integration of medical and lifestyle interventions. Listen here: https://lnkd.in/gV8eqV3X 💬 Access & Cost to Anti-Obesity Medication with Chronis Manolis: Chronis provided a payor and provider perspective, discussing the economic and logistical challenges of GLP-1s with Julie Yoo, Daisy Wolf, and William Shrank. The group discussed the importance of making these medications accessible while ensuring they are used appropriately to maximize benefits and manage costs effectively. Listen here: https://lnkd.in/gvbByzGF Together, these experts shed light on the promising future of GLP-1 medications and the ongoing efforts to balance innovation with practical implementation in healthcare.

Dive into our latest study published in BMC Health Services Research for an illuminating view of Sinai's Diabetes Center's innovative, team-based care model. We explore the benefits, challenges, and potential impact on health outcomes in diverse urban settings. Learn more here: https://lnkd.in/gSW8wAdp #DiabetesCare #HealthServicesResearch #SUHI

Before Ozempic® and Wegovy® were household names, we were building Calibrate to change the way the world treats weight and upend longstanding paradigms within a broken healthcare system that values reactive, fee-for-service care over preventative care and long-term results. In our Founder & CEO Isabelle Kenyon's words: “The future of obesity care delivers lasting outcomes while decreasing the total cost of care. That starts with educating payors on the value-based model that exists when the right kind of comprehensive, integrated GLP-1 treatment is delivered as a solution.” Read more about our vision here: https://lnkd.in/emKnVvMJ

People with diabetes deserve access to the highest quality, clinically effective, technology-based solutions to help manage their condition. Nishan Sunthares, ABHI’s Executive Director Diagnostics, was pleased this month to host ABHI’s Diabetes Group meeting at the DiabetesUK conference, to discuss ways to raise access to these technologies. The national rollout of hybrid closed loop technologies for managing type 1 diabetes is underway and the industry is committed to working with NHS England, the Diabetes Technology Network, support groups and others to ensure that those who need these technologies can benefit from them as quickly as possible. Assisting healthcare professionals identify eligible individuals, providing training and supporting their transition to HCL technologies are some of the vital activities industry is involved in. Other attendees of our members meeting included Prof Partha Kar Dr Alistair Lumb and Ameneh Ghazal S., We are incredibly grateful for their engagement and clinical leadership of this agenda. How else can HealthTech organisations improve diabetes care? Check out the priorities that our Diabetes Group are working towards: https://lnkd.in/gSnX9MB8 #Diabetes #Diabetescare #healthtech #innovation #healthcare #NHS #medtech

#Patient_Support_Equipment Market 2023 - Overview By Industry Trends, Growth Factor and Analysis To 2030. >> https://lnkd.in/dtB-dbsz The ageing population is a significant factor in the #demand for #healthcare #products and services which may contribute to the growth of the #patient #support #equipment #market. The increasing prevalence of chronic diseases and conditions, such as #diabetes, #heart #disease, and obesity, often require ongoing #medical #treatment and support, including patient support equipment. Stryker Hillrom Invacare Corporation Prism Medical UK Maquet Getinge Group Guldmann LINET Group SE Stiegelmeyer Group Handicare Stairlifts UK Joerns Healthcare #Patient_Support_Equipment #medical_device #business_opportunities #marketanalysis #marketresearch #opportunities #business #future #patient #support #equipment

𝗛𝗮𝘃𝗲 𝘆𝗼𝘂 𝗿𝗲𝗮𝗱 𝗼𝘂𝗿 𝗛𝗲𝗮𝗿𝗶𝗻𝗴 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗩𝗼𝗶𝗰𝗲𝘀 𝘀𝘂𝗿𝘃𝗲𝘆?  410 people from across Australia and other nations completed this survey in late 2021 and early 2022. The aim of the survey was to better understand the impacts of chronic UTI on individuals, as well as potential impacts on the health system and society in general. Four key themes emerged from our research: 1. Chronic UTI severely impacts quality-of-life. 2. Poor healthcare experiences are common among chronic UTI patients. 3. People with chronic UTI feel let down by diagnostic and treatment failures. 4. Health professionals’ lack of knowledge and expertise in diagnosing and treating chronic UTI results in costs to the health system that could be avoided. You can read the full survey report here: https://lnkd.in/gfyShBbV #chronicuti #cutia #patientresearch #patientoutcomes #hearingpatientvoices

I feel like a broken record, but here's what I have to say on a few topics related to #Zepbound and other #obesity #medications.... 😍 Thanks Jessica Sager for interviewing me for your Parade article "Thinking About Trying Mounjaro or Zepbound? Here's What You Can Expect Week by Week." 💉 APPROPRIATE PRESCRIBING Anti-obesity medications are not 'vanity drugs' meant for people of normal weight to lose five pounds. They are medical treatments for the #disease of obesity. Zepbound is a powerful medication that has many potential #risks if not prescribed or taken appropriately. Before starting Zepbound, it’s critical to have a healthcare provider or ideally a care team who practices #evidence-based medical #weightmanagement. It’s the Wild West out there right now with inappropriate prescribing and prescribing without education or support. ⚖ WEIGHT PLATEAUS Plateaus don't happen because the medication stops working, but because someone's body is fighting back. This is a process called metabolic adaptation. If a plateau happens before #health goals are achieved, the care team can assess the situation and decide on next steps. 📈 WEIGHT REGAIN AFTER STOPPING A MEDICATION Anti-obesity medications like Zepbound should not be used for short-term weight loss, but rather long-term treatment of obesity, which is a chronic disease requiring lifelong intervention. We prepare patients to be on an anti-obesity medication (or some type of medical obesity treatment) long-term for their chronic disease, which is only controlled for the duration of time they’re treated. Stopping Zepbound or another anti-obesity medication is a setup for weight regain (which can be sudden or insidious) for most individuals. Weight-related health complications that had been controlled on an anti-obesity medication may no longer be controlled when the medication is stopped. ENTIRE ARTICLE: https://lnkd.in/efdPbVSK PHOTO: Sandy Huffaker for The Washington Post via Getty Images Intellihealth #FlyteMedical

What's the key to GLP-1 success? Our Chief Medical Officer, Linda Anegawa, MD, FACP, Dipl. ABOM, NBPAS, joined the Becker's Healthcare podcast to talk in more detail about clinical support for payers, including GLP-1 medication management, and why lifestyle and behavior change is so essential for GLP-1 therapy success. Listen in here: